Exenatide ER is a Synthetic Peptide owned by AstraZeneca, and is involved in 29 clinical trials, of which 25 were completed, and 4 are ongoing.

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of glucagon-like peptide-1 (GLP-1). The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind to and activate the known human GLP-1 receptor in vitro, its mechanism of action mediated by cyclic AMP and/or other intracellular signaling pathways. Exenatide suppresses glucagon secretion which is known to be inappropriately elevated in patients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) is an intestinal incretin hormone secreted during meals, and increasing evidence indicates it plays a role in satiation. As GLP-1 acts to augment prandial insulin secretion, small-molecule GLP-1 receptor agonists are prescribed as an adjunct treatment for type 2 diabetes.

The revenue for Exenatide ER is expected to reach a total of $3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Exenatide ER NPV Report.

Exenatide ER is currently owned by AstraZeneca.

Exenatide ER Overview

Exenatide (Bydureon/Bydureon BCise/Byetta Long) is a naturally occuring peptide. It is formulated as an extended-release injectable powder for suspension and suspension for subcutaneous route of administration. It is indicated for the treatment of type 2 diabetes mellitus. It is used with the combination of metformin, sulphonylurea, thiazolidinedione, metformin and sulphonylurea, metformin and thiazolidinedione, basal insulin in adults.

AstraZeneca Overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.

Quick View – Exenatide ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Exenatide ER
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.